Haemophilus Influenzae Infections

Also known as: Haemophilus Influenza Infections / Haemophilus influenza infection / Hemophilus influenza infection / Haemophilus influenzae infection / Hemophilus influenzae infection / Haemophilus infection / Haemophilus Infections / Haemophilus infection NOS / Hemophilus infection

DrugDrug NameDrug Description
DB00207AzithromycinAzithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration [A174172]. It was initially approved by the FDA in 1991 [A174175]. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin [A174169]. Azithromycin [9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin] is a part of the _azalide_ subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides [A174175].
DB00254DoxycyclineDoxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline [FDA label]. This drug is a second-generation tetracycline, exhibiting lesser toxicity than first-generation tetracyclines [A174034]. Doxycycline may be used to treat a wide range of bacterial infections, depending on the results of antibiotic susceptibility testing.
DB00199ErythromycinErythromycin is an antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the _macrolide_ group of antibiotics [FDA label]. It was originally discovered in 1952. Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive bacteria, gram-negative bacteria and many other organisms [L5245], [FDA label].